HARARE – With 14 percent of Zimbabwe’s population living with HIV/Aids and tuberculosis as a co-infection, the need for new drugs and new formulations of available treatments is crucial. To address these issues, University at Buffalo’s leading research centres, the Institute for Lasers, Photonics and Biophotonics (ILPB), and the New York State Centre of Excellence…
To access this content, please purchase a subscription by clicking the button below and select a package of your choice!
Subscriptions